KAI-1/CD82, the molecule and clinical implication in cancer and cancer metastasis

Histology and Histopathology

Volumn 24, Issue 4, 2009, Pages 519-530

  Malik, Fraz Arshad ^a,b   Sanders, Andrew J ^a   Jiang, Wen G ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b Department of Electrical Computer Engineering   (Pakistan)

Author keywords

Cancer; Cancer metastasis; CD82; Invasion; KAI 1

Indexed keywords

CD82 ANTIGEN; DECORIN; TETRASPANIN; EPIDERMAL GROWTH FACTOR RECEPTOR; TUMOR MARKER;

APOPTOSIS; BREAST CANCER; CANCER SURVIVAL; CELL ADHESION; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL INVASION; CELL MEMBRANE; CELL MIGRATION; CHROMOSOME 11; DIGESTIVE SYSTEM CANCER; DOWN REGULATION; EMBRYO DEVELOPMENT; ENDOCYTOSIS; ENDOPLASMIC RETICULUM; EXON; EXTRACELLULAR MATRIX; GENE EXPRESSION PROFILING; GENE MUTATION; GENE STRUCTURE; GYNECOLOGIC CANCER; HUMAN; INTRON; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; OSTEOCLAST; POLYMERASE CHAIN REACTION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN METHYLATION; PROTEIN STABILITY; REVIEW; SIGNAL TRANSDUCTION; SOFT TISSUE SARCOMA; UROGENITAL TRACT CANCER; CANCER INVASION; CELL TRANSFORMATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY; PREGNANCY; VIRUS ATTACHMENT;

CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KANGAI-1 PROTEIN; NEOPLASM INVASIVENESS; NEOPLASMS; PREGNANCY; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; VIRUS ATTACHMENT;

EID: 63449119328     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (129)

1. Abe M., Sugiura T., Takahashi M., Ishii K., Shimoda M. and Shirasuna K. (2008). A novel functions of CD82/KAI-1 on E-cadherin-mediated homophilic cellular adhesion of cancer cells. Cancer Lett. 8, 163-70.
2. Arihiro K. and Inai K. (2001). Loss of KAI1/CD82 expression in bone and soft tissue tumors is not associated with lung metastasis. Pathol. Res. Pract. 9, 627-633.
3. Aryee D.N.T., Ambros I., Ambros P.F., Muehlbacher K., Luegmayr Yoshie O. and Kovar H. (2002). Frequent low level expression in Ewing sarcoma family tumors and widespread absence of the metastasis suppressor KAI1/ CD82 in neuroblastoma Pediatric Res. 52, 279-285
4. Bass R., Werner F., Odintsova E., Sugiura T., Berditchevski F.D. and Ellis V. (2005). Regulation of urokinase receptor proteolytic function by the tetraspanin CD82. J. Biol. Chem. 280, 14811-14818.
5. Berditchevski F. (2001). Analysis of the CD151-α1ß3 integrin and CD151-tetraspanin interactions by mutagenesis. J. Biol. Chem. 276, 41165-44174.
6. Bonifacino J.S. and Traub L.M. (2003). Signals for sorting of transmembrane proteins to endosomes and lysosomes. Annu. Rev. Biochem. 72, 395-447.
7. Boyd S., Tolvanen K., Virolainen S., Kuivanen T., Kyllönen L. and Saarialho-Kere U. (2008). Differential expression of stromal MMP-1, MMP-9 and TIMP-1 in basal cell carcinomas of immunosuppressed patients and controls. Virchows Arch. 452, 83-90.
8. Briese J., Schulte H.M., Sajin M., Bamberger C., Redlin K., Milde-Langosch K., Loöning T. and Bamberger A-M. (2008). Correlations between reduced expression of the metastasis suppressor gene KAI-1 and accumulation of p53 in uterine carcinomas and sarcomas. Virchows Archiv. 453, 89-96.
9. Cannon K.S. and Cresswell P. (2001). Quality control of transmembrane domain assembly in the tetraspanin CD82. EMBO J. 20, 2443-2453.
10. Chen Z., Mustafa T., Trojanowicz B., Brauckhoff M., Gimm O., Schmutzler C., Koöhrle J., Hoang-Vu C. (2004). CD82, and CD63 in thyroid cancer. Int. J. Mol. Med. 14, 517-527.
11. Cho S. (2006). Introduction of KAI1/CD82 gene suppressed metastatic ability of LNCaP human prostate cancer cells in SCID mouse model. Teikyo Med. J. 29, 195-203.
12. Condeelis J. and Pollard J.W. (2006). Macrophages: Obligate partners for tumor cell. Migration, invasion, and metastasis. Cell 124, 263-266.
13. Crotta S., Ronconi V., Ulivieri C., Baldari C.T., Valiente N.M., Abrignani S. and Wack A. (2006). Cytoskeleton rearrangement induced by tetraspanin engagement modulates the activation of T and NK cells. Eur. J. Immunol. 36, 919-929.
14. Delaguillaumie A., Harriague J., Kohanna S., Bismuth G., Rubinstein E., Seigneuret M. and Conjeaud H. (2004). Tetraspanin CD82 controls the association of cholesterol-dependent microdomains with actin cytoskeleton in T lymphocytes: Relevance to co-stimulation. J. Cell Sci. 117, 5269-5282.
15. Dong J-T, Lamb P.W., Rinker-Schaeffer C.W., Vukanovic J., Ichikawa T., Isaacs J.T. and Barrett J.C. (1995). KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science. 268, 884-886.
16. Drucker L., Tohami T., Tartakover-Matalon S., Zismanov V., Shapiro H., Radnay J. and Lishner M. (2006). Promoter hypermethylation of tetraspanin members contributes to their silencing in myeloma cell lines. Carcinogenesis 27, 197-204.
17. Duriez C., Falette N., Cortes U., Moyret-Lalle C. and Puisieux A. (2000). Absence of p53-dependent induction of the metastatic suppressor KAI1 gene after DNA damage. Oncogene 19:2461-2464.
18. Eshchenko T. Yu, Rykova V.I., Chernakov A.E., Sidorov S.V. and Grigorieva E.V. (2007). Expression of different proteoglycans in human breast tumors. Biochemistry 72, 1016-20.
19. Farhadieh R.D., Smee R., Ow K., Yang J.L., Russell P.J., Crouch R., Jackson P., Jacobson I.V. (2004). Down-regulation of KAI1/CD82 protein expression in oral cancer correlates with reduced disease free survival and overall patient survival. Cancer Lett. 213, 91-98.
20. Friess H., Guo X.Z., Berberat P., Graber H.U., Zimmermann A., Korc M. and Büchler M.W. (1998) Reduced KAI1 expression in pancreatic cancer is associated with lymph node and distant metastases. Int. J. Cancer 79, 349-355.
21. Fromont G., Vallancien G., Validire P., Levillain P. and Cussenot O. (2007). BCAR1 expression in prostate cancer: association with 16q23 LOH status, tumor progression and EGFR/KAI1 staining. Prostate 15, 268-273.
22. Gao A.C., Lou W., Dong J-T., Barrett J.C., Danielpour D. and Isaacs J.T. (2003). Defining regulatory elements in the Human KAI1 (CD 82) Metastasis Suppressor Gene. Prostate 57, 256-260.
23. Garcia E., Pion M., Matthews P.A., Collinson L, Arrighi J.F., Blot G., Leuba F. and Piguet V. (2005). HIV-1 trafficking to the dendritic cell-T-cell infectious synapse uses a pathway of tetraspanin sorting to the immunological synapse. Traffic 6, 488-501.
24. Gaugitsch H.W., Hofer E., Huber N.E, Schnabl E. and Baumruker T. (1991). A new superfamily of lymphoid and melanoma cell proteins with extensive homology to Schistosoma mansoni antigen Sm23. Eur. J. Immunol. 21, 377-383.
25. Gellersen B., Briese J., Oberndörfer M., Redlin K., Samalecos A., Richter D.U., Looning T. and Bamberger A.M. (2007). Expression of the metastasis suppressor KAI1 in decidual cells at the human maternal-fetal interface: Regulation and functional implications. Am. J. Pathol. 170, 126-139.
26. Guo X.Z., Xu J.H., Liu M.P., Kleeff J., Ho C.K., Ren L.N., Li H.Y. and Friess H. (2005). KAI1 inhibits anchorage-dependent and - independent pancreatic cancer cell growth. Oncol. Rep. 14, 59-63.
27. Halasz P., Fleming F.E. and Coulson B.S. (2005). Evaluation of specificity and effects of monoclonal antibodies submitted to the Eighth Human Leucocyte Differentiation Antigen Workshop on rotavirus-cell attachment and entry. Cell. Immunol. 236, 179-187.
28. Hammond C., Denzin L.K., Pan M., Griffith J.M., Geuze H.J. and Cresswell P. (1998). The tetraspan protein CD82 is a resident of MHC class II compartments where it associates with HLADR, -DM and -DO molecules. J. Immunol. 161, 3282-329.
29. He B., Liu L., Cook G.A., Grgurevich S., Jennings L.K. and Zhang X.A. (2005). Tetraspanin CD82 attenuates cellular morphogenesis through down-regulating integrin α6-mediated cell adhesion. J. Biol. Chem. 280, 3346-3354.
30. Hemler M.E. (2001). Specific tetraspanin functions, J. Cell Biol. 155, 1103-1108.
31. Hemler M.E. (2005). Tetraspanin functions and associated microdomains. Nat. Rev. Mol. Cell Biol. 6, 801-811.
32. Herbst R.S. (2004). Review of epidermal growth factor receptor biology. Int. J. RadiationOncol. Biol. Phys. 59, 21-26.
33. Houle C.D., Ding X.Y., Foley J.F., Afshari C.A., Barrett J.C. and Davis B.J. (2002). Loss of expression and altered localization of KAI1 and CD9 protein are associated with epithelial ovarian cancer progression. Gynecol Oncol. 86, 69-78.
34. Hu C-CA., Liang F.X., Zhou G., Tu L., Tang CH.A., Zhou J., Kreibich G. and Sun T.T. (2005). Assembly of urothelial plaques: Tetraspanin function in membrane protein trafficking. Mol. Biol. Cell 16, 3937-3950.
35. Huai Q., Mazar A.P., Kuo A., Parry G.C., Shaw D.E., Callahan J., Li Y., Yuan C., Bian C., Chen L., Furie B., Furie B.C., Cines D.B. and Huang M. (2006). Structure of human urokinase plasminogen activator in complex with its receptor. Science 3, 656-659.
36. Huang H., Groth J., Sossey-Alaoui K., Hawthorn L., Beall S. and Geradts J. (2005). Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumours. Clin. Cancer Res. 15, 4357-4364.
37. Ichikawa T., Ichikawa Y. and Isaacs J.T. (1991). Genetic factors and suppression of metastatic ability of prostatic cancer. Cancer Res. 51, 3788-3792.
38. Imai T. and Yoshie O. (1993). C33 antigen and M38 antigen recognized by monoclonal antibodies inhibitory to syncytium formation by human T cell leukemia virus type 1 are both members of the transmembrane 4 superfamily and associate with each other and with CD4 or CD8 in T cells. Immunology 151, 6470-6481.
39. Imai T., Kakizaki M., Nishimura M. and Yoshie O. (1995). Molecular analyses of the association of CD4 with two members of the transmembrane 4 superfamily, CD81 and CD82. J. Immunol. 155, 1229-1239.
40. Ito Y., Uruno T., Takamura Y., Miya A., Kobayashi K., Matsuzuka F., Kuma K. and Miyauchi A. (2005). Papillary microcarcinomas of the thyroid with preoperatively detectable lymph node metastasis show significantly higher aggressive characteristics on immunohistochemical examination. Oncology 68, 87-96.
41. Iwai K., Ishii M., Ohshima S., Miyatake K. and Saeki Y. (2007). Expression and function of transmembrane-4 superfamily (tetraspanin) proteins in osteoclasts: Reciprocal roles of Tspan-5 and NET-6 during osteoclastogenesis. Allergol. Int. 56, 457-463.
42. Jackson P., Ow K., Yardley G., Delprado W., Quinn D.I., Yang J.L. and Russell P.J. (2003). Downregulation of KAI1mRNAin localized prostate cancer and its bony metastases do not correlate with p53 overexpression. Prostate Cancer Prostatic Dis. 6, 174-181.
43. Jackson P., Rowe A. and Grimm M.O. (2007). An alternatively spliced KAI1 mRNA is expressed at low levels in human bladder cancers and bladder cancer cell lines and is not associated with invasive behaviour. Oncol. Rep.18, 1357-1363.
44. Jee B., Jin K., Hahn J.H., Song H.G. and Lee H.(2003). Metastasis-suppressor KAI1/CD82 induces homotypic aggregation of human prostate cancer cells through Src-dependent pathway. Exp. Mol. Med. 35, 30-37.
45. Jee B.K., Park K.M., Surendran S., Lee W.K., Han C.W., Kim Y.S. and Lim Y. (2006). KAI1/CD82 suppresses tumor invasion by MMP9 inactivation via TIMP1 up-regulation in the H1299 human lung carcinoma cell line. Biochem. Biophys. Res. Commun. 342, 655-661.
46. Jee B.K., Lee J.Y., Lim Y., Lee K.H. and Jo Y.H.(2007). Effect of KAI1/ CD82 on the β1 integrin maturation in highly migratory carcinoma cells. Biochem. Biophys. Res. Commun. 359, 703-708.
47. Jiang W-X., Song B-G., Tang R-Y. and Fang J-P. (2006). Metastatic suppressor Kangai 1 in primary gallbladder carcicoma: Expression and clinical significance. Acad. J. Second Mil Med. Univ. 27, 1101-1104.
48. Kim J.H., Kim B., Cai L., Choi H.J., Ohgi K.A., Tran C., Chen C., Chung C.H., Huber O., Rose D.W., Sawyers C.L., Rosenfeld M.G. and Baek S.H. (2005). Transcriptional regulation of a metastasis suppressor gene by Tip60 and beta-catenin complexes. Nature 434, 921-926.
49. Kim J.H., Choi H.J., Kim B., Kim M.H. and Lee J.M. (2006). Roles of sumoylation of a reptin chromatin remodelling complex in cancer metastasis. Nat. Cell Biol. 8, 631-639.
50. Kim K.I. and Baek S.H. (2006). SUMOylation code in cancer development and metastasis. Mol. Cell 22, 247-253.
51. Kopczynska E., Kwapisz J., Junik R. and Tyrakowski T. (2007). Cellular tumor markers in thyroid cancer. Polski Merkuriusz Lekarski 22, 295-299.
52. Kovalenko O.V., Yang X., Kolesnikova T.V. and Hemler M.E. (2004). Evidence for specific tetraspanin homodimers: inhibition of palmitoylation makes cysteine residues available for cross linking. Biochem. J. 377, 407-417.
53. Lagaudriere-Gesbert C., Naour F.L., Lebel-Binay S., Billard M., Lemichez E., Boquet P., Boucheix C. and Rubinstein E. (1997). Functional analysis of four tetraspans, CD9, CD53, CD81, and CD82, suggests a common role in co stimulation, cell adhesion, and migration: Only CD9 upregulates HB-EGF activity. Cell. Immunol. 182, 105-112.
54. Leavey P.J., Timmons C., Frawley W., Lombardi D. and Ashfaq R. (2006). KAI-1 expression in pediatric high-grade osteosarcoma. Pediatr. Dev. Pathol. 2006. 9, 219-224.
55. Lee J.H., Seo Y.W., Park S.R., Kim Y.J. and Kim K.K. (2003). Expression of a splice variant of KAI1, a tumor metastasis suppressor gene, influences tumor invasion and progression. Cancer Res. 63, 7247-7255.
56. Lee J.H., Park S.R., Chay K.O., Seo Y.W., Kook H., Ahn K.Y., Kim Y.J. and Kim K.K. (2004). KAI1 COOH-Terminal interacting Tetraspanin (KITENIN), a member of the tetraspanin family, interacts with KAI1, a tumor metastasis suppressor and enhances metastasis of cancer. Cancer Res. 64, 4235-4243.
57. Lee J.H., Cho E.S., Kim M.Y., Seo Y.W., Kho D.H., Chung I.K., Kook H., Kim N.S., Ahn K.Y. and Kim K.K. (2005). Suppression of progression and metastasis of established colon tumors in mice by intravenous delivery of short interfering rna targeting kitenin, a metastasis-enhancing protein. Cancer Res. 65, 8993-9003.
58. Lekishvili T., Fromm E., Mujoomdar M. and Berditchevski F. (2008). The tumour-associated antigen L6 (L6-Ag) is recruited to the tetraspanin-enriched microdomains: Implication for tumour cell motility. J. Cell Sci. 121, 685-694.
59. Liizumi M., Bandyopadhyay S. and Watabe K. (2007). Interaction of duffy antigen receptor for chemokines and KAI1: A critical step in metastasis suppression. Cancer Res. 67, 1411-1414.
60. Liu F.S., Dong J.T., Chen J.T., Hsieh Y.T., Ho E.S. and Hung M.J. (2000). Frequent down-regulation and lack of mutation of the KAI1 metastasis suppressor gene in epithelial ovarian carcinoma. Gynecol. Oncol. 78, 10-15.
61. Liu F.S., Chen J.T., Dong J.T., Hsieh Y.T., Lin A.J., Ho E.S., Hung M.J. and Lu C.H. (2001). KAI1 metastasis suppressor gene is frequently down-regulated in cervical carcinoma. Am. J. Pathol. 159, 1629-1634.
62. Liu F.S., Dong J.T., Chen J.T., Hsieh Y.T., Ho E.S., Hung M.J., Lu C.H. and Chiou L.C. (2003). KAI1 metastasis suppressor protein is downregulated during the progression of human endometrial cancer. Clin. Cancer Res. 9, 1393-1398.
63. Liu T., Wang X., Zhu C., Li Y., Sun C. and Wang A. (2005). Expression of KAI1 protein in tissue microarray and its biological significances in patients with lung cancer. Chin. J. Lung Cancer 8, 116-119.
64. Malik F.A., Sanders A.J. and Jiang W.G. (2008a). The role of KAI-1 in the adhesive, growth and invasive capacity of breast cancer cell lines. Proc. Natl. Cancer Res. Ins. 2008, p132
65. Malik F.A., Kayani M.A., Iqbal H., Jiang W.G. and Sadiq R. (2008b). Screening of coding region of metastatis suppressor genes KISS-1 and KAI-1 for germ line mutations in breast cancer patients. Gene Ther. Mol. Biol. 12, 239-246.
66. Mantegazza A.R., Barrio M.M., Moutel S., Bover L., Weck M., Brossart P., Teillaud J.L. and Mordoh J. (2004). CD63 tetraspanin slows down cell migration and translocates to the endosomal-lysosomal-MIICs route after extracellular stimuli in human immature dendritic cells. Blood 104, 1183-1190.
67. Marreiros A., Czolij R., Yardley G., Crossley M. and Jackson P. (2003). Identification of regulatory regions within the Kai1 promoter: a role for binding of AP1, AP2 and p53. Gene 302, 155-164.
68. Martin F., Roth D.M., Jans D.A., Pouton C.W., Partridge L.J., Monk P.N. and Moseley G.W. (2005). Tetraspanins in viral infections: A fundamental role in viral biology? J. Virol. 79, 10839-10851.
69. Mashimo T., Watabe M., Hirota S., Hosobe S., Miura K., Tegtmeyer P.J., Rinker-Shaeffer C.W. and Watabe K. (1998). The expression of the KAI1 gene, a tumor metastasis suppressor, is directly activated by p53. Proc. Natl. Acad. Sci. 95, 11307-11311.
70. Matthews P.A., Kramer B. and Marsh M. (2003). Infectious HIV-1 assembles in late endosomes in primary macrophages. J. Cell Biol. 162, 443-455.
71. Mazurov D., Heidecker G. and Derse D. (2006). HTLV-1 Gag protein associates with CD82 tetraspanin microdomains at the plasma membrane. Virology 346, 194-204.
72. Mazurov D., Heidecker G. and Derse D.(2007). The inner loop of tetraspanins CD82 and CD81 mediates interactions with human T cell lymphotrophic virus type 1 gag protein. J. Biol. Chem. 282, 3896-3803.
73. Melchior F., Schergaut M. and Pichler A. (2003). SUMO: ligases, isopeptidases and nuclear pores. Trends Biochem. Sci. 28, 612-618.
74. Miyazaki T., Kato H., Shitara Y., Yoshikawa M., Tajima K., Masuda N., Shouji H., Tsukada K., Nakajima T. and Kuwano H. (2000). Mutation and expression of the metastasis suppressor gene KAI1 in esophageal squamous cell carcinoma. Cancer189, 955-962.
75. Miyazaki T., Kato H., Kimura H., Inose T., Faried A., Sohda M., Nakajima M. and Kuwano H. (2005). Evaluation of tumor malignancy in esophageal squamous cell carcinoma using different characteristic factors. Anticancer Res. 25, 4005-4011.
76. Mohan A., Nalini V., Mallikarjuna K., Jyotirmay B. and Krishnakumar S. (2007). Expression of motility-related protein MRP1/CD9, Ncadherin, E-cadherin, α-catenin and β-catenin in retinoblastoma. Exp. Eye Res. 84, 781-789.
77. Nagira M., Imai T., Ishikawa I., Uwabe K.I. and Yoshie O. (1994). Expression of tetraspanins in human lung cancer cells: frequent down regulation of CD9 and its contribution to cell motility in small cell lung cancer. Oncogene 6, 674-687.
78. Nydegger S., Khurana S., Krementsov D.N., Foti M. and Thali M. (2006). Mapping of tetraspanin-enriched microdomains that can function as gateways for HIV-1. J. Cell Biol. 173, 795-807.
79. Odintsova E., Sugiura T. and Berditchevski F. (2000). Attenuation of EGF receptor signaling by a metastasis suppressor, the tetraspanin CD82/ KAI-1. Curr. Biol. 10, 1009-1012.
80. Odintsova E., Voortman J., Gilbert E. and Berditchevski F. (2003). Tetraspanin CD82 regulates compartmentalisation and ligand-induced dimerization of EGFR. J. Cell Sci. 116, 4557-4566.
81. Odintsova E., Butters T.D., Monti E., Sprong H., Van Meer G. and Berditchevski F.(2006), Gangliosides play an important role in the organization of CD82-enriched microdomains. Biochem. J. 400, 315-325.
82. Ono M. and Hakomori S. (2004). Glycosylation defining cancer cell motility and invasiveness. Glycoconjugate J. 20, 71-78.
83. Plantefaber L.C. and Hynes R. (1989). Changes in integrin receptors on oncogenically transformed cells. Cell 56, 281-290.
84. Protzel C., Kakies C., Kleist B., Poetsch M. and Giebel J. (2008). Down-regulation of the metastasis suppressor protein KAI1/CD82 correlates with occurrence of metastasis, prognosis and presence of HPV DNA in human penile squamous cell carcinoma. Virchows Arch. 452, 369-375.
85. Ravanti L. and Kahari V.M. (2000). Matrix metalloproteinases in wound repair. Int. J. Mol. Med. 6, 391-407.
86. Rotterud R., Fosså S.D. and Nesland J.M. (2007). Protein networking in bladder cancer: Immunoreactivity for FGFR3, EGFR, ERBB2, KAI1, PTEN, and RAS in normal and malignant urothelium. Histol. Histopathol. 22, 349-363.
87. Rowe A. and Jackson P. (2006). Expression of KITENIN, a KAI1/CD82 binding protein and metastasis enhancer, in bladder cancer cell lines: relationship to KAI1/CD82 levels and invasive behaviour. Oncol. Rep. 16, 1267-1272.
88. Rubinstein E., Naour F. Le., Lagaudriere-Gesbert, Billard M., Conjeaud H. and Boucheix C. (1996). CD9, CD63, CD81, and CD82 are components of a surface tetraspan network connected to HLA-DR and VLA integrins. Eur. J. Immunol. 26, 2657-2665.
89. Schindi M., Birner P., Bachtiary B., Breitenecker G., Selzer E. and Oberhuber G. (2000). The impact of expression of the metastasis suppressor protein KAI1 on prognosis in invasive squamous cell cervical cancer. Anticancer Res.20, 4551-4555.
90. Schoenfeld N., Bauer M.K. and Grimm S. (2004). The metastasis suppressor gene C33/CD82/KAI1 induces apoptosis through reactive oxygen intermediates. FASEB J. 18,158-160.
91. Seigneuret M.A., Delaguillaumie C., Lagaudriere-Gesbert C. and Conjeaud H. (2001). Structure of the tetraspanin main extracellular domain. A partially conserved fold with a structurally variable domain insertion. J. Biol. Chem. 276, 40055-40064.
92. Skubitz K.M., Campbell K.D., Iida J. and Skubitz A.P.N. (1996). CD63 associates with tyrosine kinase activity and CD11/CD18, and transmits an activation signal in neutrophils. J. Immunol. 157, 3617-3626.
93. Sho M., Adachi M., Taki T., Hashida H., Konishi T., Huang CL., Ikeda N., Nakajima Y., Kanehiro H., Hisanaga M., Nakano H. and Miyake M.(1998). Transmembrane 4 superfamily as a prognostic factor in pancreatic cancer. Int. J. Cancer 79, 509-516.
94. Son B.H., Choi J.S. and Lee J.H. (2005). Prognostic values of KAI1 and survivin expression in an infiltrating ductal carcinoma of the breast. Pathology 37, 131-136.
95. Sridhar S.C. and Miranti C.K. (2006). Tetraspanin KAI1/CD82 - dependent crosstalk with c-Met receptor and Src kinases, Oncogene 25, 2367-2378.
96. Stark A.M., Tongers K., Maass N., Mehdorn H.M. and Held Feindt J. (2005). Reduced metastasis-suppressor gene mRNA-expression in breast cancer brain metastases. J. Cancer Res. Clin Oncol. 131, 191-198.
97. Stipp C.S., Kolesnikova T.V. and Hemler M.E. (2003). Functional domains in tetraspanin proteins. Trends Biochem. Sci. 28, 106-112.
98. Su J.S., Arima K., Hasegawa M., Franco O.E., Umeda Y., Yanagawa M., Sugimura Y. and Kawamura J. (2004). Decreased expression of KAI1 metastasis suppressor gene is a recurrence predictor in primary pTa and pT1 urothelial bladder carcinoma. Int. J. Urology 11, 74-82.
99. Sweeney C., Miller J.K., Shattuck D.L. and Carraway III K.L. (2006). ErbB receptor negative regulatory mechanisms: Implications in cancer. J. Mammary Gland Biol. Neoplasia 11, 89-99.
100. Tagawa K., Arihiro K., Takeshima Y., Hiyama E., Yamasaki M. and Inai K. (1999). Down-regulation of KAI1 messenger RNA expression is not associated with loss of heterozygosity of the KAI1 gene region in lung adenocarcinoma. Jpn. J. Cancer Res. 90, 970-976.
101. Takayama G., Taniguchi A. and Okano T. (2007). Identification of differentially expressed genes in hepatocyte / endothelial cell coculture system. Tissue Engineering 13, 159-166.
102. Takeda T., Hattori N., Tokuhara T., Nishimura Y., Yokoyama M. and Miyake M. (2007). Adenoviral transduction of MRP-1/CD9 and KAI1/CD82 inhibits lymph node metastasis in orthotopic lung cancer model. Cancer Res. 67, 1744-1749.
103. Tarrant J.M., Robb X.L., Van Spriel A.B. and Wright M.D. (2003). Tetraspanins: molecular organisers of the leukocyte surface. Trends Immunol. 24, 610-617.
104. Telese F., Bruni P., Donizetti A., Gianni D., D'Ambrosio C., Scaloni A., Zambrano N. and Russo T. (2005). Transcription regulation by the adaptor protein Fe65 and the nucleosome assembly factor SET. EMBO Rep. 6, 77-82.
105. Todeschini A.R., Dos Santos J.N., Handa K. and Hakomori S.I. (2007). Ganglioside gm2-tetraspanin cd82 complex inhibits met and its cross-talk with integrin, providing a basis for control of cell motility through glycosynapse. Biol. Chem. 282, 8123-8133.
106. Todeschini A.R., Dos Santos J.N., Handa K. and Hakomori S.I. (2008). Ganglioside GM2/GM3 complex affixed on silica nanospheres strongly inhibits cell motility through CD82/cMet-mediated pathway. Proc. Natl. Acad. Sci. 105, 1925-1930.
107. Tohami T., Drucker L., Shapiro H., Radnay J. and Lishner M. (2007). Overexpression of tetraspanins affects multiple myeloma cell survival and invasive potential. FASEB J. 21, 691-699.
108. Toyo-Oka K., Yashiro-Ohtani Y., Park C.S., Tai G.X., Miyake K., Hamaoka T. and Fujiwara H. (1999). Association of a tetraspanin CD9 with CD5 on the T cell surface: role of particular transmembrane domains in the association. Int. Immunol. 11, 2043-2052.
109. Tsai Y.C., Mendoza A., Mariano J.M., Zhou M., Kostova Z., Chen B., Veenstra T. and Weissman A.M. (2007). The ubiquitin ligase gp78 promotes sarcoma metastasis by targeting KAI1 for degradation. Nature Med. 13, 1504-1509.
110. Tsutsumi S., Shimura T., Morinaga N., Mochiki E., Asao T. and Kuwano H. (2005). Loss of KAI1 expression in gastric cancer. Hepato-Gastroenterology 52, 281-284.
111. Venugopal C., Pappolla M.A. and Sambamurti K. (2007). Insulysin cleaves the APP cytoplasmic fragment at multiple sites. Neurochem. Res. 32, 2225-2234.
112. Vogt A.B., Spindeldreher S. and Kropshofer H. (2002). Clustering of MHC-peptide complexes prior to their engagement in the immunological synapse: Lipid raft and tetraspan microdomains. Immunol. Rev. 189, 136-151.
113. Wang X.Y., Liu T., Zhu C.Z., Li Y., Sun R., Sun C.Y. and Wang A.X. (2005). Expression of KAI1, MRP-1, and FAK proteins in lung cancer detected by high-density tissue microarray. Chin. J. Cancer 24, 1091-1095.
114. Wang G., Li M. and Liu Z. (2006). Expression and significance of KAI1/ CD82 and E-Cadherin in human squamous cervical carcinoma. J. Xi'an Jiaotong Univ. 27, 274-277.
115. Welsch S., Keppler O.T., Habermann A., Allespach I., Krijnse-Locker J. and Kraäusslich H.G. (2007). HIV-1 buds predominantly at the plasma membrane of primary human macrophages. PLoS Pathogens 3, 11-15.
116. White A., Lamb P.W. and Barrett J.C. (1998). Frequent down regulation of the KAI1 (CD82) metastasis suppressor protein in human cancer cell lines, Oncogene 16, 3143-3149.
117. Willett B.J., Flynn J.N. and Hosie M.J. (1997). FIV infection of the domestic cat: an animal model for AIDS. Immunology 18, 182-189.
118. Wu Z.L., Wu Z.H. and Guo X. (2003). Study on the expression of the metastasis suppressor gene KAI1 in laryngeal squamous cell carcinoma. Zhonghua Er Bi Yan Hou Ke Za Zhi. 38, 413-416.
119. Wu Q., Ji Y., Zhang M.Q., Chen Y.Q., Chen F., Shi D.L., Zheng Z.H. and Su W.J. (2003). Role of tumor metastasis suppressor gene KAI1 in digestive tract carcinomas and cancer cells. Cell Tissue Res. 314, 237-249.
120. Wu X.R., Zhu M.H. and Zhang Z.D. (2005). Expression of KAI1/CD82 in neuroblastoma and its correlation to prognosis. Chin. J. Cancer 24, 885-889.
121. Yang X., Wei L., Tang C., Slack R., Montgomery E. and Lippman M. (2000). KAI1 protein is down-regulated during the progression of human breast cancer. Clin. Cancer Res. 6, 3424-3429.
122. Yauch R.L. and Hemler M.E. (2000). Specific interactions among transmembrane 4 superfamily (TM4SF) proteins and phosphoinositide 4-kinase. Biochem. J. 351, 629-637.
123. Yuan H.G., Song X.F., Zhang P., Long B., Dong Z.Q., Xu X.M., Zhou T.G. and Chen X.G. (2008). Expression of KAI1 in urothelial cancer tissues and its relationship with invasion and metastasis of urothelial cancer. J. Second Mil. Med. Univ. 29, 189-192
124. Yunta M. and Lazo P.A. (2003). Tetraspanin proteins as organisers of membrane microdomains and signalling complexes. Cell. Signal. 15, 559-564.
125. Zhang X.A., Bontrager A.L. and Hemler M.E. (2001). Transmembrane-4 Superfamily Proteins Associate with Activated Protein Kinase C (PKC) and Link PKC to Specific β1 Integrins. J. Biol. Chem. 276, 25005-25013.
126. Zhang X.A, Lane W.S., Charrin S., Rubinstein E. and Liu L. (2003). EWI2/ PGRL associates with the metastasis suppressor KAI1/CD82 and inhibits the migration of prostate cancer cells. Cancer Res. 63, 2665-2674.
127. Zheng H.C., Wang M.C., Li J.Y., Yang X.F., Sun J.M. and Xin Y. (2004). Expression of maspin and KAI1 and their clinicopathological significance in carcinogenesis and progression of gastric cancer. Chin. Med. Sci. J. 19, 193-198.
128. Zhou B., Liu L., Reddivari M. and Zhang X.A. (2004). The palmitoylation of metastasis suppressor KAI1/CD82 is important for its motility- and invasiveness-inhibitory activity. Cancer Res. 64, 7455-7463.
129. Zijlstra A. and Quigley J.P.(2006). The DARC side of metastasis: Shining a light on KAI1-mediated metastasis suppression in the vascular tunnel. Cancer Cell 10, 177-178.